360 related articles for article (PubMed ID: 11433225)
41. When heparin causes thrombosis: significance, recognition, and management of heparin-induced thrombocytopenia in dialysis patients.
Chang JJ; Parikh CR
Semin Dial; 2006; 19(4):297-304. PubMed ID: 16893407
[TBL] [Abstract][Full Text] [Related]
42. [Heparin-induced thrombocytopenia. New therapeutical options].
Seculini Patiño CE; Tabares AH
Medicina (B Aires); 2016; 76(4):230-4. PubMed ID: 27576282
[TBL] [Abstract][Full Text] [Related]
43. Heparin-induced thrombocytopenia: diagnosis and management.
Liebman HA
Vascular; 2008; 16 Suppl 1():S71-6. PubMed ID: 18544310
[TBL] [Abstract][Full Text] [Related]
44. The identification and management of heparin-induced thrombocytopenia in the vascular patient.
LaMuraglia GM; Houbballah R; Laposata M
J Vasc Surg; 2012 Feb; 55(2):562-70. PubMed ID: 22188737
[TBL] [Abstract][Full Text] [Related]
45. Serotonin release assay (SRA)-negative HIT, a newly recognized entity: Implications for diagnosis and management.
Pandya KA; Johnson EG; Davis GA; Padmanabhan A
Thromb Res; 2018 Dec; 172():169-171. PubMed ID: 30419472
[No Abstract] [Full Text] [Related]
46. Distinct Binding Characteristics of Pathogenic Anti-Platelet Factor-4/Polyanion Antibodies to Antigens Coated on Different Substrates: A Perspective on Clinical Application.
Nguyen TH; Greinacher A
ACS Nano; 2018 Dec; 12(12):12030-12041. PubMed ID: 30540167
[TBL] [Abstract][Full Text] [Related]
47. Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery.
Selleng S; Malowsky B; Itterman T; Bagemühl J; Wessel A; Wollert HG; Warkentin TE; Greinacher A
Am Heart J; 2010 Aug; 160(2):362-9. PubMed ID: 20691844
[TBL] [Abstract][Full Text] [Related]
48. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia.
Whitlatch NL; Perry SL; Ortel TL
Thromb Haemost; 2008 Oct; 100(4):678-84. PubMed ID: 18841292
[TBL] [Abstract][Full Text] [Related]
49. Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity.
Brandt S; Krauel K; Gottschalk KE; Renné T; Helm CA; Greinacher A; Block S
Thromb Haemost; 2014 Jul; 112(1):53-64. PubMed ID: 24671506
[TBL] [Abstract][Full Text] [Related]
50. HITlights: a career perspective on heparin-induced thrombocytopenia.
Warkentin TE
Am J Hematol; 2012 May; 87 Suppl 1():S92-9. PubMed ID: 22367928
[TBL] [Abstract][Full Text] [Related]
51. Anti-PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis.
Warkentin TE; Sheppard JI; Sun JC; Jung H; Eikelboom JW
J Thromb Haemost; 2013 Feb; 11(2):253-60. PubMed ID: 23216710
[TBL] [Abstract][Full Text] [Related]
52. An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients.
Kannan M; Saxena R; Adiguzel C; Fareed J
Semin Thromb Hemost; 2009 Apr; 35(3):337-43. PubMed ID: 19452409
[TBL] [Abstract][Full Text] [Related]
53. Performance of a new, rapid, automated immunoassay for the detection of anti-platelet factor 4/heparin complex antibodies.
Davidson SJ; Ortel TL; Smith LJ
Blood Coagul Fibrinolysis; 2011 Jun; 22(4):340-4. PubMed ID: 21415710
[TBL] [Abstract][Full Text] [Related]
54. Heparin-platelet factor 4 antibodies in patients presenting to the ED with thrombosis.
Francis JL; Drexler A; Duncan MK; Walker JM; Hursting MJ; Levine RL
Am J Emerg Med; 2007 Mar; 25(3):279-84. PubMed ID: 17349901
[TBL] [Abstract][Full Text] [Related]
55. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia.
Huynh A; Kelton JG; Arnold DM; Daka M; Nazy I
Nature; 2021 Aug; 596(7873):565-569. PubMed ID: 34233346
[TBL] [Abstract][Full Text] [Related]
56. New approaches to the diagnosis of heparin-induced thrombocytopenia.
Warkentin TE
Chest; 2005 Feb; 127(2 Suppl):35S-45S. PubMed ID: 15706029
[TBL] [Abstract][Full Text] [Related]
57. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation.
Newman PM; Chong BH
Blood; 2000 Jul; 96(1):182-7. PubMed ID: 10891449
[TBL] [Abstract][Full Text] [Related]
58. The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis.
Carrier M; Knoll GA; Kovacs MJ; Moore JC; Fergusson D; Rodger MA
Thromb Res; 2007; 120(2):215-20. PubMed ID: 17098277
[TBL] [Abstract][Full Text] [Related]
59. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI.
Kasthuri RS; Glover SL; Jonas W; McEachron T; Pawlinski R; Arepally GM; Key NS; Mackman N
Blood; 2012 May; 119(22):5285-93. PubMed ID: 22394597
[TBL] [Abstract][Full Text] [Related]
60. Heparin-induced thrombocytopenia: frequency and pathogenesis.
Greinacher A
Pathophysiol Haemost Thromb; 2006; 35(1-2):37-45. PubMed ID: 16855345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
